Archive

Category Archives for "immunotherapy"

What Makes This Gerson Cancer Treatment Different at CHIPSA?

gerson chipsa

The history of CHIPSA Hospital is in a way, the history of Gerson Therapy itself. We are known as the Gerson Therapy hospital because our hospital was founded by Charlotte Gerson, the daughter of Max Gerson, the man who created the Gerson Immuno-Nutrition Protocol. The hospital that is now CHIPSA began using the Gerson Protocols […]

Continue reading

Research Team Discovers New Immune “Checkpoint” Protein

immunotherapy

A recent report in the journal Cell showed that a team led by Vanderbilt researchers has found a new “checkpoint” protein on immune system cells in active, malignant tumors. In mouse models, blocking this protein, along with using other treatments, has been an effective approach to treating cancerous cells. Checkpoint proteins are an important component of […]

Continue reading

Study Shows Better Immunotherapy Outcomes in Tumors with More Mutations

Immunotherapy

A recent study published in Nature Genetics called “Tumor mutational load predicts survival after immunotherapy across multiple cancer types” revealed that tumors with more mutations had better results with immunotherapy treatment. The study looked at data from 1,662 metastatic cancer patients who received checkpoint inhibitor therapy, and data from over 5,000 patients who were not treated […]

Continue reading

Researchers Use AI to Improve Immunotherapy Outcomes

immunotherapy

A research team from the University of Maryland is utilizing artificial intelligence (AI) to determine the most effective ways to treat cancer patients with immunotherapy. Immunotherapy takes advantage of the body’s own immune system to fight off cancer, and in the past decade, it has been very successful in treating patients with localized and advanced […]

Continue reading

Phase 3 Trial Tests Tyvyt as Esophageal Cancer Therapy

esophageal cancer

The ORIENT-15 Phase 3 clinical trial evaluating Tyvyt (sintilimab injection) combined with chemotherapies Taxol (paclitaxel) and Platinol (cisplatin) as treatment for esophageal squamous cell carcinoma is now underway. Tyvyt was developed by Innovent Biologics and Eli Lilly and Company in China as an immune checkpoint inhibitor that will work against PD-1, a protein found on […]

Continue reading

Tecentriq Triple Combo Under FDA Review for NSCLC Treatment

NSCLC

Genetech has announced that the U.S. Food and Drug Administration (FDA) will be reviewing its Tecentriq (atezolizumab) combined with chemotherapy drugs Abraxane (nab-paclitaxel) and carboplatin for treatment of metastatic non-squamous non-small cell lung cancer (NSCLC). The drug will be for patients without any mutations in the EGFR and ALK genes.   Tecentriq is a checkpoint inhibitor drug that targets […]

Continue reading